These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 9949205)

  • 1. Methylation profiling of CpG islands in human breast cancer cells.
    Huang TH; Perry MR; Laux DE
    Hum Mol Genet; 1999 Mar; 8(3):459-70. PubMed ID: 9949205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting aberrant CpG island methylation.
    Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12253-8. PubMed ID: 14519846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation.
    McCabe MT; Lee EK; Vertino PM
    Cancer Res; 2009 Jan; 69(1):282-91. PubMed ID: 19118013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase.
    Vertino PM; Yen RW; Gao J; Baylin SB
    Mol Cell Biol; 1996 Aug; 16(8):4555-65. PubMed ID: 8754856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer.
    Yan PS; Perry MR; Laux DE; Asare AL; Caldwell CW; Huang TH
    Clin Cancer Res; 2000 Apr; 6(4):1432-8. PubMed ID: 10778974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.
    Ahluwalia A; Yan P; Hurteau JA; Bigsby RM; Jung SH; Huang TH; Nephew KP
    Gynecol Oncol; 2001 Aug; 82(2):261-8. PubMed ID: 11531277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
    Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
    Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays.
    Yan PS; Chen CM; Shi H; Rahmatpanah F; Wei SH; Caldwell CW; Huang TH
    Cancer Res; 2001 Dec; 61(23):8375-80. PubMed ID: 11731411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of the p16(Ink4a) tumor suppressor gene 5'-CpG island in breast cancer.
    Nielsen NH; Roos G; Emdin SO; Landberg G
    Cancer Lett; 2001 Feb; 163(1):59-69. PubMed ID: 11163109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes.
    Chen CM; Chen HL; Hsiau TH; Hsiau AH; Shi H; Brock GJ; Wei SH; Caldwell CW; Yan PS; Huang TH
    Am J Pathol; 2003 Jul; 163(1):37-45. PubMed ID: 12819009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
    Roll JD; Rivenbark AG; Jones WD; Coleman WB
    Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation leads to silencing of the SYK gene in human breast cancer.
    Yuan Y; Mendez R; Sahin A; Dai JL
    Cancer Res; 2001 Jul; 61(14):5558-61. PubMed ID: 11454707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
    Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
    Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the cytosine DNA-methyltransferase and p16INK4a genes in the development of mouse lung tumors.
    Belinsky SA
    Exp Lung Res; 1998; 24(4):463-79. PubMed ID: 9659578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation.
    Graff JR; Herman JG; Myöhänen S; Baylin SB; Vertino PM
    J Biol Chem; 1997 Aug; 272(35):22322-9. PubMed ID: 9268383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of ER gene CpG island methylation-specific polymerase chain reaction.
    Lapidus RG; Nass SJ; Butash KA; Parl FF; Weitzman SA; Graff JG; Herman JG; Davidson NE
    Cancer Res; 1998 Jun; 58(12):2515-9. PubMed ID: 9635570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
    Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
    J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.